http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 17:59:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Whitehawk+Therapeutics%2C++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26933076.html si-local-file:///var/storage/secattach/20260814/26933076.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Whitehawk+Therapeutics%2C++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26933076.html Fri, 14 Aug 2026 17:59:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Whitehawk+Therapeutics%2C++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26933076.html si-local-file:///var/storage/secattach/20260814/26933076.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Whitehawk+Therapeutics%2C++++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26933076.html Fri, 14 Aug 2026 17:59:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Whitehawk+Therapeutics%2C++++++++++++++++Filed+by%3A+ABG+Management+Ltd./26931625.html si-local-file:///var/storage/secattach/20260814/26931625.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Whitehawk+Therapeutics%2C++++++++++++++++Filed+by%3A+ABG+Management+Ltd./26931625.html Fri, 14 Aug 2026 16:35:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Whitehawk+Therapeutics%2C++++++++++++++++Filed+by%3A+ABG+Management+Ltd./26931625.html si-local-file:///var/storage/secattach/20260814/26931625.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Whitehawk+Therapeutics%2C++++++++++++++++Filed+by%3A+ABG+Management+Ltd./26931625.html Fri, 14 Aug 2026 16:35:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+30/26883483.html si-local-file:///var/storage/secattach/20260806/26883483.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+30/26883483.html Thu, 06 Aug 2026 16:04:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+30/26883483.html si-local-file:///var/storage/secattach/20260806/26883483.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+30/26883483.html Thu, 06 Aug 2026 16:04:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Whitehawk+Therapeutics%2C+++For%3A+Aug+06/26880955.html si-local-file:///var/storage/secattach/20260806/26880955.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Whitehawk+Therapeutics%2C+++For%3A+Aug+06/26880955.html Thu, 06 Aug 2026 10:08:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Whitehawk+Therapeutics%2C+++For%3A+Aug+06/26880955.html si-local-file:///var/storage/secattach/20260806/26880955.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Whitehawk+Therapeutics%2C+++For%3A+Aug+06/26880955.html Thu, 06 Aug 2026 10:08:00 -0400 O.37125755 WHWK http://www.streetinsider.com/Earnings/Whitehawk+Therapeutics%2C+Inc.+%28WHWK%29+Tops+Q2+EPS+by+11c/26879855.html <p>Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) reported Q2 EPS of ($0.20), $0.11 better than the analyst estimate of ($0.31).</p><p>For earnings history and earnings-related data on Whitehawk Therapeutics, Inc. (WHWK) <a href="http://www.streetinsider.com/ec_earnings.php?q=WHWK">click here</a>.</p> http://www.streetinsider.com/Earnings/Whitehawk+Therapeutics%2C+Inc.+%28WHWK%29+Tops+Q2+EPS+by+11c/26879855.html Thu, 06 Aug 2026 08:36:38 -0400 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html <div class="xn-content"> <p class="prntac"><i>Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026</i></p><p class="prntac"><i>Cash, cash equivalents and short-term investments of</i> <i><money>$190.0 million</money></i> <i>as of <chron>June 30, 2026</chron>, anticipated to fund operations into 2H 2028</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended <chron>June 30, 2026</chron>, and provided recent corporate highlights.</p><p>"The http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Highlights/26879171.html Thu, 06 Aug 2026 08:00:00 -0400 A.29463264 A.50216726 O.12972128 O.21612337 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Dalal+Anupam/26843446.html si-local-file:///var/storage/secattach/20260730/26843446.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Dalal+Anupam/26843446.html Thu, 30 Jul 2026 16:04:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Dalal+Anupam/26843446.html si-local-file:///var/storage/secattach/20260730/26843446.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+May+14++Filed+by%3A+Dalal+Anupam/26843446.html Thu, 30 Jul 2026 16:04:00 -0400 O.37125755 WHWK http://www.streetinsider.com/New+Coverage/Leerink+Assumes+Whitehawk+Therapeutics+%28WHWK%29+at+Outperform/26796283.html <p>Leerink analyst Asthika Goonewardene assumes coverage on Whitehawk Therapeutics (NASDAQ: WHWK) with a Outperform rating and a price target of $9.00.</p> <p>For an analyst ratings summary and ratings history on Whitehawk Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=WHWK">click here</a>. For more ratings news on Whitehawk Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=WHWK&amp;type=analyst">click here</a>.</p> <p>Shares of Whitehawk Therapeutics closed at $3.79 yesterday.</p> http://www.streetinsider.com/New+Coverage/Leerink+Assumes+Whitehawk+Therapeutics+%28WHWK%29+at+Outperform/26796283.html Tue, 21 Jul 2026 16:50:00 -0400 WHWK http://www.streetinsider.com/New+Coverage/Leerink+Starts+Whitehawk+Therapeutics+%28WHWK%29+at+Outperform/26759194.html <p>Leerink initiates coverage on Whitehawk Therapeutics (NASDAQ: WHWK) with a Outperform rating and a price target of $9.00.</p> <p>For an analyst ratings summary and ratings history on Whitehawk Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=WHWK">click here</a>. For more ratings news on Whitehawk Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=WHWK&amp;type=analyst">click here</a>.</p> <p>Shares of Whitehawk Therapeutics closed at $3.97 yesterday.</p> http://www.streetinsider.com/New+Coverage/Leerink+Starts+Whitehawk+Therapeutics+%28WHWK%29+at+Outperform/26759194.html Mon, 13 Jul 2026 06:04:02 -0400 WHWK